Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Enfortumab Vedotin with Radiation in MIBC
NCT05879653Phase 2Recruiting
- Sponsor
- Kyoto University Hospital
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, enfortumab vedotin in muscle-invasive bladder cancer (MIBC), sponsored by Kyoto University Hospital. Started Oct 2023; status: recruiting.
02
Drugs
pembrolizumabenfortumab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05879653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879653.